Eli Lilly has reported positive topline results from TRANSCEND-T2D-2, a Phase 3 trial that directly compared its investigational triple hormone receptor agonist retatrutide with Novo Nordisk’s Ozempic at the 2 mg dose in adults with type 2 diabetes. The company disclosed the results on October 29 alongside its third-quarter earnings. Retatrutide met the study’s primary objective and, at both tested maintenance doses, produced greater weight loss than the active comparator while delivering the same average reduction in glycated haemoglobin, or A1C.

The open-label trial randomised 1,298 adults whose diabetes was inadequately controlled with metformin, with or without an SGLT2 inhibitor. After 80 weeks, average A1C fell by 2.2 percentage points in both the 9 mg and 12 mg retatrutide groups, compared with a 1.8-point reduction for Ozempic 2 mg. Lilly said both retatrutide doses achieved statistical superiority on the A1C comparison. The result places the candidate in a strong efficacy position, although the topline disclosure does not yet provide the full statistical plan, subgroup findings or detailed baseline characteristics needed for a complete assessment.

The separation was larger on body weight. Participants assigned to retatrutide lost an average 19.5 percent of body weight at 9 mg and 20.9 percent at 12 mg, compared with 9.4 percent for Ozempic. These are unusually large reductions for a diabetes population, where weight loss can be harder to achieve than in obesity-only trials because of disease duration, concomitant medicines and metabolic differences. Retatrutide activates the GIP, GLP-1 and glucagon receptors, a design intended to combine appetite and glucose effects with increased energy expenditure. It remains investigational and is not approved by any regulator.

Safety and tolerability will be central to how clinicians and regulators interpret the efficacy advantage. Lilly reported discontinuations due to adverse events in 4.8 percent of participants receiving 9 mg, 7.9 percent receiving 12 mg and 2.7 percent receiving Ozempic. The company characterised the overall safety profile as consistent with previous incretin studies, but the higher discontinuation rate at the top dose is an important counterweight to the additional weight loss. Detailed rates of gastrointestinal events, serious adverse events, treatment interruptions and dose reductions were not included in the initial announcement.

Why it matters: the comparison moves the next generation of incretin development from placebo-controlled efficacy toward direct competition with an established standard. Ozempic 2 mg is a commercially successful and clinically familiar treatment. Beating it on both A1C and weight creates a clearer value proposition than showing superiority to placebo, but it does not settle questions about cardiovascular outcomes, long-term safety, real-world adherence, manufacturing capacity or payer access. Those factors may determine whether retatrutide can translate trial performance into broad use.

The result also sharpens competitive pressure across the metabolic pipeline. Developers are advancing oral GLP-1 drugs, amylin combinations, next-generation dual agonists and other multi-receptor approaches. A candidate capable of approximately 20 percent average weight loss in type 2 diabetes raises the efficacy benchmark, yet competing products may differentiate on convenience, tolerability, preservation of lean mass, cardiovascular benefit or price. Head-to-head trials will become increasingly important as the market becomes less tolerant of comparisons made across unrelated studies.

Lilly said detailed results will be presented at a future medical meeting and submitted for publication. Until then, the disclosure should be treated as company-reported topline evidence rather than a peer-reviewed dataset. The next questions include whether the two doses differ materially across patient subgroups, how much of the benefit was maintained among people who stayed on treatment, and whether the additional efficacy at 12 mg justifies its higher discontinuation rate.

The trial also illustrates why dose selection is becoming a strategic issue for high-efficacy metabolic medicines. The 9 mg dose delivered nearly the same average weight reduction as 12 mg with fewer adverse-event discontinuations in the topline figures. That does not prove it has the better benefit-risk balance, because the groups may differ on other safety and efficacy measures. It does show that a future label, titration schedule and commercial presentation may need to support individualised dosing rather than treating the highest dose as the automatic destination.